Doctors Lounge -- Antiplatelet therapy in hypertensive patients with chronic kidney disease significantly reduces cardiovascular events and mortality, outweighing a nonsignificant increase in major bleeding risk, according to research published in the Sept. 14 issue of the Journal of the American College of Cardiology.
